SAN DIEGO, Feb. 24, 2020 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders,
today announced that the company will participate in four
upcoming investor conferences.
Details of the company's participation are as follows:
- Raymond James 41st
Annual Institutional Investors Conference
Details: Viking
management will deliver a corporate presentation and participate in
1-on-1 meetings
Time/Date: 9:15 a.m. Eastern on
Monday, March 2, 2020
Location: JW Marriott Grande Lakes, Orlando, FL
- Cowen and Company 40th Annual Health Care
Conference
Details: Viking management will deliver a
corporate presentation and participate in 1-on-1 meetings
Time/Date: 9:20 a.m. Eastern on
Wednesday, March 4, 2020
Location: Boston Marriott Copley Place
- 32nd Annual ROTH Conference
Details:
Viking management will deliver a corporate presentation and
participate in 1-on-1 meetings
Time/Date: 10:00 a.m. Pacific on
Monday, March 16, 2020
Location: Ritz Carlton Laguna Niguel, Dana Point, CA
- Oppenheimer 30th Annual Healthcare
Conference
Details: Viking management will deliver a
corporate presentation and participate in 1-on-1 meetings (webcast
available)
Time/Date: 8:00 a.m. Eastern on
Tuesday, March 17, 2020
Location: InterContinental New York Barclay
To access the live webcast of the Oppenheimer presentation,
please visit "Webcasts & Presentations" within the News &
Events section of Viking's Investors page at
www.vikingtherapeutics.com. Additionally, a replay of the webcast
will be available on the Viking website following the
conference.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel, orally available,
first-in-class or best-in-class therapies for the treatment of
metabolic and endocrine disorders. Viking's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the treatment of lipid and metabolic
disorders, including NASH. In a Phase 2 trial for the
treatment of NAFLD and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received
placebo. The company is also developing VK0214, a novel,
orally available, small molecule selective thyroid hormone receptor
beta agonist for the treatment of X-linked adrenoleukodystrophy
(X-ALD).
Viking's other programs include VK5211, an orally available,
non-steroidal selective androgen receptor modulator. In a
Phase 2 trial in patients recovering from hip fracture, patients
who received VK5211 experienced significant improvements in
measures of lean body mass compared with patients who received
placebo. Other programs also include VK0612, a
first-in-class, orally available drug candidate in Phase 2
development for the treatment of type 2 diabetes as well as two
earlier-stage programs targeting metabolic diseases and
anemia. The company holds exclusive worldwide rights to a
portfolio of five therapeutic programs, including those noted
above, which are based on small molecules licensed from Ligand
Pharmaceuticals Incorporated.
Follow Viking on Twitter @Viking_VKTX.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-upcoming-investor-conferences-301009579.html
SOURCE Viking Therapeutics, Inc.